Navigation Links
Review and approval of oncology and hematology drugs at FDA from 2005 to 2007
Date:1/29/2010

Over a two and half year period, beginning in 2005 when the U.S. Food and Drug Administration's oncology drug product's office began reviewing marketing applications, a total of 60 new oncology and hematology drugs were reviewed, of which 53 were approved, according to a new article published online January 29 in the Journal of the National Cancer Institute.

To provide an overview of recent regulatory actions by the FDA's Office of Oncology Drug Products in the Center for Drug Evaluation and Research, Rajeshwari Sridhara, Ph.D., of the FDA's Office of Biostatistics, in Silver Spring, Md., and colleagues identified all applications reviewed, as well as actions taken, from July 1, 2005, through December 31, 2007. Their review included "New Drug Application" and "Biologics Licensing Application" approvals.

Marketing applications for 60 new products were reviewed and regulatory action was taken on 58 of them based on a riskbenefit evaluation. Products that demonstrated efficacy and had an acceptable riskbenefit ratio (i.e., the magnitude of the treatment effect was statistically persuasive and clinically meaningful) were granted either regular or accelerated marketing approval. A total of 53 new indications were approved: 39 received regular approval, nine received accelerated approval, and five were converted from accelerated to regular approval. Two applications were withdrawn before action was taken, and five were not approved.

Approvals were based on various study designs and primary outcomes or endpoints. Some approvals were from single-arm, non-randomized controlled trials in cases when the FDA deemed it impractical to conduct randomized studies.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants less ... best drug option for each patient. Dentists have several general anesthesia alternatives and finding ... Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out which ...
(Date:1/17/2017)... ... 2017 , ... For breast cancer clinicians and researchers who were unable to ... more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th ... Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology ... of the Year. , Each year, Pink Elephant recognizes a new product ... to address a specific business problem or opportunity. The award highlights original innovations that ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group ... infusing high speed technology into the fabric of an entire community. A highlight ... healthcare and wellness in a yet-to-be-named, health focused campus. Leading this initiative in ...
(Date:1/17/2017)... Utah (PRWEB) , ... January 17, 2017 , ... ... of accredited, online continuing education for EMS and firefighting professionals, has released four ... (VILT) Solution. These new courses are taught live in an online classroom and ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017 ML Capital ... to publish an online presentation tomorrow, January 19 ... forecast for 2017. Management reports that the forecast ... sales performance from its existing operations, and the ... into the Cannabis sector through a partnership ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... Jan. 17, 2017 North America Insulin Delivery ... report, "North America Insulin Delivery Market Outlook to 2022", ... Delivery market. The report provides value, in millions of ... within market segments - Insulin Pens, Insulin Pumps, Insulin ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: